Haha look I think there would be plenty of reasons as to why Lilly is doing well, but first and foremost the entire pharmaceutical industry in the US is going gangbusters.
Acrux is a very different company to Lilly, and as a biotech with essentially only the one revenue generating product, it's far riskier.
I only put the Lilly chart up to show that the whole Axiron thing has not impacted them in the slightest. I know it a small product for them, but it's still good to see.
I'm sick of waiting for Acrux to jump a little in price, but I'm confident they'll do well in their full year results, and I'm waiting for a nice dividend!
Add to My Watchlist
What is My Watchlist?
